Harrow (NASDAQ:HROW) Stock Price Down 4.6% – Should You Sell?

Posted by Hanz Christensen on Feb 2nd, 2025

Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) traded down 4.6% on Friday . The stock traded as low as $30.50 and last traded at $30.22. 72,615 shares were traded during trading, a decline of 75% from the average session volume of 288,269 shares. The stock had previously closed at $31.69.

Analysts Set New Price Targets

Separately, B. Riley decreased their price target on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

View Our Latest Analysis on Harrow

Harrow Stock Performance

The business’s fifty day simple moving average is $35.93 and its 200-day simple moving average is $39.52. The firm has a market cap of $1.09 billion, a P/E ratio of -32.68 and a beta of 0.72. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Institutional Trading of Harrow

Several large investors have recently modified their holdings of the business. Quest Partners LLC purchased a new stake in Harrow in the 3rd quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after acquiring an additional 227 shares in the last quarter. Hills Bank & Trust Co purchased a new stake in Harrow in the third quarter worth $107,000. Huntington National Bank bought a new stake in Harrow in the third quarter valued at $164,000. Finally, Clarus Group Inc. purchased a new position in Harrow during the 3rd quarter valued at $225,000. 72.76% of the stock is owned by institutional investors.

About Harrow

(Get Free Report)

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.